Organogenesis Holdings Inc. (ORGO)

Organogenesis Holdings Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	37.03	0.86	4.95	15.53	94.2
Depreciation & Amortization	26.94	25.37	23.45	18.03	16.68
Stock-Based Compensation	13.3	10.58	9	6.55	3.86
Other Adjustments	45.67	25.98	11.04	18.83	-15.75
Change in Receivables	-115.8	-31.8	5.54	-8.77	-28.65
Changes in Inventories	-17.92	-6.2	-8.18	-9.41	-9.3
Changes in Accounts Payable	-0.53	-2.37	-0.11	3.26	3.85
Changes in Accrued Expenses	0.16	-1.06	0.09	-11.85	9.35
Changes in Other Operating Activities	-18.98	-2.41	12.36	-7.31	-12.26
Operating Cash Flow	10.38	9.16	3.14	24.86	61.98
Operating Cash Flow Growth	13.28%	192.03%	-87.38%	-59.89%	1033.88%
Capital Expenditures	-14.15	-10.03	-24.36	-33.9	-31.22
Investing Cash Flow	-14.15	-10.03	-24.36	-33.9	-31.22
Short-Term Debt Repaid	-	-	-	-	-10
Net Short-Term Debt Issued (Repaid)	-	-	-	-	-10
Long-Term Debt Issued	-	-	-	-	73.17
Long-Term Debt Repaid	-	-66.56	-4.69	-2.81	-62.56
Net Long-Term Debt Issued (Repaid)	-	-66.56	-4.69	-2.81	10.62
Issuance of Common Stock	0.16	1.25	-	2.07	2.2
Repurchase of Common Stock	-1.89	-26.65	-0.33	-0.65	-0.74
Net Common Stock Issued (Repurchased)	-1.73	-25.41	-0.33	1.42	1.46
Issuance of Preferred Stock	-	120.69	-	-	-
Net Preferred Stock Issued (Repurchased)	-	120.69	-	-	-
Other Financing Activities	-15.63	-1.08	-0.49	-0.81	-3.11
Financing Cash Flow	-17.36	27.64	-5.51	-2.2	-1.04
Net Cash Flow	-21.13	26.77	-26.83	-11.24	29.72
Free Cash Flow	-3.77	-0.87	-21.23	-9.04	30.76
FCF Margin	-0.67%	-0.18%	-4.90%	-2.00%	6.58%
Free Cash Flow Per Share	-0.03	-0.01	-0.16	-0.07	0.23
Levered Free Cash Flow	-4.46	-64.2	3.51	-28.46	71.92
Unlevered Free Cash Flow	10.76	3.69	9.21	-24.1	84.94

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q